Additional sex comb-like (ASXL) genes are human homologues of Drosophila-Asx gene which encode important regulators of gene expression. ASXL1 mutations occur at high frequencies in multiple forms of myeloid malignancy patients with poor prognosis. ASXL1 mutations are mostly nonsense/frameshift, causing truncation of the protein lacking the C-terminal PHD finger, which is detectable in patient samples with ASXL1 mutations. We have recently shown that transgenic expression of an ASXL1 truncation in mice (Asxl1Y588XTg) results in increased HSC/HPC pools and pathogenesis of myeloid malignancies (Blood 2017). BAP1 is activated by ASXL1 to deubiquitinate H2AK119 during polycomb protein-mediated gene repression. BAP1 mutations also occur in patients with MDS. Despite the significant impact of ASXL1 truncation mutations on the pathogenesis of myeloid malignancies, the underlying mechanisms remain largely unknown, hindering the development of effective targeted therapeutics. Our proteomics studies discovered that ASXL1aa1-587 exhibits an increased binding affinity to BAP1 compared to ASXL1FL and gains an interaction with BRD4, a member of the BET family. BRD4 is involved in multiple biologic processes, including transcription, DNA replication, epigenetic regulation, and tumorigenesis. We hypothesize that truncated ASXL1 dysregulates HSC/HPCs and causes myeloid malignancies through altering the function of the BAP1 deubiquitinase complex and gaining interaction with BRD4. Challenging this critical question has great translational impact and is the major goal of this application.
In Aim 1, we will use our recently generated Tet-on/off Asxl1Y588XTg mice to assess in prove- of-concept whether silencing transgene expression by withdrawing doxycycline can eradicate the ASXL1aa1-587- mediated abnormal hematopoietic phenotype and myeloid malignancies. We will apply bPPI-seq, a novel sensitive assay to confirm/identify the true ASXL1aa1-587 interactors at physiological conditions in vivo.
In Aim 2, we will determine the role of BRD4-ASXL1aa1-587 interaction in truncated ASXL1-mediated HSC/HPC dysregulation and myeloid malignancy development. We will examine whether BRD4 inhibitor (EP11313) treatment is capable of preventing and/or rescuing the abnormal hematopoietic phenotype and myeloid malignancies in Asxl1Y588XTg mice.
In Aim 3, we will determine the role of BAP1 in truncated ASXL1-mediated abnormal HSC/HPC behavior and pathogenesis of myeloid malignancies in vivo. We will decipher how ASXL1aa1-587 alters the function of BAP1 in HSC/HPCs in vivo. The effects of ASXL1aa1-587 on genome-wide BAP1 and H2AK119Ub occupancy in LK cells will be determined by ChIP-seq and correlated with the gene expression data. These studies are timely and fundamentally important for advancing our knowledge on ASXL1 truncation mutation-mediated HSC/HPC dysregulation and myeloid malignancy development. The success of this project will likely identify novel therapeutic targets in the gained-interactors for ASXL1 truncation, BRD4 and BAP1, for the treatment of myeloid malignancies with ASXL1 truncation mutations.
The goal of our studies is to identify the molecular mechanisms by which truncated ASXL1 leads to the pathogenesis of myeloid malignancies and identify novel therapeutic targets. This study may lead to identification of therapeutic targets for ASXL1 truncation mutation-mediated myeloid malignancies, thus has great translational impact.
Showing the most recent 10 out of 16 publications
